By: Chelsie Derman
Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.
Chelsie Derman is an associate editor for HCPLive. She covers a range of topics within medicine and healthcare, focusing on areas such as psychiatry, sleep medicine, geriatrics, and allergies, while also exploring themes related to mental health care and pharmaceuticals. Chelsie's work has been featured in Contemporary Pediatrics, AJMC - The American Journal of Managed Care, Drug Topics, Contemporary OB/GYN, NewsBreak, Cliggott Publishing Co, HCP Live, and RamaOnHealthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Chelsie's articles mainly focus on healthcare and medical research, with an emphasis on citing data. She would likely be interested in pitches that involve new or significant findings within the healthcare and pharmaceutical industries, particularly those backed by robust data.
Given her focus on scientific topics related to mental health, treatment, diseases, and medical research, Chelsie may respond well to pitches involving groundbreaking studies or clinical trials in these areas. Pitches supported by strong empirical evidence or access to experts involved in conducting such research are likely to resonate with her.
As there is no specified geographic focus for Chelsie's coverage, she appears open to global perspectives and developments within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .